Skip to main content
SpringerLink
Log in

Histrelin Hydrogel Implant — Valera

Histrelin Implant, LHRH-Hydrogel Implant, RL 0903, SPD 424

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Valera Pharmaceuticals. Valera Pharmaceuticals Begins Patient Enrollment for a Phase III Study of a Twelve-Month Implant for the Treatment of Central Precocious Puberty. Media Release: 8 Sep 2004. Available from URL: http://www.ValeraPharma.com

    Google Scholar 

  2. Schlegel PN, Moo-Young A, Kuzma P. Long term effectiveness of testicular androgen suppression with a GnRH agonist, delivered by a hydrogel implant. Journal of Urology 153 (Suppl.): 451, Apr 1995

    Google Scholar 

  3. Chertin B, Spitz IM, Lindenberg T, et al. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. Journal of Urology 163: 838–844, Mar 2000

    Article  PubMed  CAS  Google Scholar 

  4. Schlegel PN, Kuzma P, Frick J, et al. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology 58: 578–582, Oct 2001

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Histrelin Hydrogel Implant — Valera. Drugs in R D 6, 53–55 (2005). https://doi.org/10.2165/00126839-200506010-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200506010-00007

Keywords

Search

Navigation